title: Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate.
abstract: OBJECTIVE
  Brimonidine is a third-generation selective alpha-2 adrenergic agonist that lowers intraocular pressure by decreasing aqueous humor production and increasing uveoscleral flow. Its safety profile for children <2 years of age remains unknown.
  
  
  METHODS
  We describe a case of ingestion of a single drop of brimonidine 0.2% in a newborn, resulting in sedation, cardiorespiratory depression, and hyperglycemia within minutes.
  
  
  CONCLUSIONS
  This report adds to the existing evidence that brimonidine can have serious adverse side effects and should therefore be used with extreme caution in infants <2 years of age. Additionally,safety procedures like double-checking should also include vitamins or oral supplements to improve medication safety in the neonatal intensive care unit.
authors: Neonatal Intensive Care Unit, Division Woman and Child, University Hospitals-Campus Gasthuisberg, Leuven - Belgium. sophie.vanhaesebrouck@uzleuven.be
authors: Sophie
authors: S
authors: Vanhaesebrouck
authors: Veerle
authors: V
authors: Cossey
authors: Katrien
authors: K
authors: Cosaert
authors: Karel
authors: K
authors: Allegaert
authors: Gunnar
authors: G
authors: Naulaers
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000506:poisoning*; D000959:Antihypertensive Agents / Q000506:poisoning; D001919:Bradycardia / Q000139:chemically induced* / Q000175:diagnosis; D000068438:Brimonidine Tartrate; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000175:diagnosis; D007231:Infant, Newborn; D008297:Male; D008508:Medication Errors; D011810:Quinoxalines / Q000506:poisoning*; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D011810:Quinoxalines; D000068438:Brimonidine Tartrate